TIDMYGEN
RNS Number : 5136W
Yourgene Health PLC
26 April 2021
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
Further National Microbiology Framework contract awards
Successful tenders under Lots 2 & 3 valued at a total of
GBP4bn
Yourgene one of only three companies to have been successfully
awarded under all four lots
Manchester, UK - 26 April 2021: Yourgene (AIM: YGEN), the
international molecular diagnostics group, announces that Public
Health England ("PHE") has confirmed that Yourgene has been
successful with its tenders under PHE's National Microbiology
Framework for Lot 2 (Research and Development Goods and Services)
and Lot 3 (Manufacturing, Product Development and
Commercialisation).
Lot 2 is a GBP1.5bn Framework to be satisfied over a period of
two years by multiple successful bidders, with 69 companies
appointed to this lot. Similarly, Lot 3 is also a GBP2.5bn
Framework to be satisfied over two years, but with only 9 suppliers
appointed to this lot.
PHE's National Microbiology Framework appoints suppliers to
framework agreements for four lots. Yourgene has now been
successful in all four of these lots and is one of only three
companies to do so. The lots are summarised below:
Value Duration
Lot 1: Diagnostic Goods and Services GBP3bn 4yrs
Lot 2: Research and Development Goods and GBP1.5bn 2yrs
Services
Lot 3: Manufacturing, Product Development GBP2.5bn 2yrs
and Commercialisation
Lot 4: Clinical Laboratory Diagnostic Testing GBP15bn 2yrs
Services
Yourgene will be able to offer its Clarigene (R) SARS-CoV-2 PCR
assay and associated Manchester-based clinical laboratory testing
services under the National Microbiology Framework Agreement , as
well as other testing or test development services.
Whilst the Framework Agreement is not exclusive to Yourgene, or
a guarantee of orders, it does allow participating public health
authorities across the UK to issue call-off contracts to procure
goods and testing services from Yourgene, amongst other providers,
going forward.
Lyn Rees, CEO of Yourgene commented:
"We are delighted with the successful tender award under both
Lot 2 and 3 of the Microbiology Framework, alongside the previous
awards. I can only reiterate that this is a testament to the
quality and credibility of our accredited lab based COVID testing
services.
"Over the last year we have built up an infectious disease
business with an impressive testing capacity and a best-in-class
product, and have done so without taking our focus away from our
core business. We are now well positioned to compete for the next
wave of contracts under this framework, particularly as one of only
three companies successful in all four lots. We believe this has
been the right approach to deliver value to our shareholders as we
continue to deliver year-on-year revenue growth and position
ourselves strongly in both the private and Government testing
markets over the next two years. As and when we secure future
call-off contracts under these framework agreements we will provide
further updates."
This announcement contains inside information for the purposes
of UK Market Abuse Regulation. The Directors of the Company take
responsibility for this announcement.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584 391
303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFELLLFZLXBBL
(END) Dow Jones Newswires
April 26, 2021 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024
